Holen Sie sich die Stockscreener-App
11.81
2.96%
0.34
Handel nachbörslich:
11.81
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results - The Manila Times
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights - Benzinga
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November - The Manila Times
Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's lead-212 edge - Investing.com India
1,602,283 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Purchased by Nicholson Wealth Management Group LLC - MarketBeat
Perspective Therapeutics (NYSE:CATX) Shares Gap UpStill a Buy? - MarketBeat
Perspective Therapeutics initiated with a Buy at UBS - TipRanks
Perspective Therapeutics (NYSE:CATX) Given Outperform Rating at Wedbush - MarketBeat
Market undervaluing Perspective Therapeutics stock amid upcoming trial data, says UBS - Investing.com
Perspective Therapeutics (NYSE:CATX) Now Covered by UBS Group - MarketBeat
Perspective Therapeutics presents updates at 37th Annual Congress of EANM - TipRanks
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine - The Manila Times
Immunodeficiency Therapeutics Market Analysis by Industry - openPR
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been enviable, earning 685% in 5 years - Simply Wall St
Oppenheimer maintains outperform rating on CATX shares amid new data - Investing.com India
Siemens Healthineers Gets FDA Clearance for Alzheimer’s Disease Analysis Features - Imaging Technology News
The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World
Perspective Therapeutics Inc (CATX) Shares Up 4.38% on Oct 16 - GuruFocus.com
Perspective begins shipping investigational products from facility in NJ - TipRanks
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - The Manila Times
Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey - Marketscreener.com
Perspective Therapeutics (NYSE:CATX) Trading Up 4.9%Should You Buy? - MarketBeat
Perspective Therapeutics Inc (CATX) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Perspective Therapeutics stock rises despite initial confusion over VMT01 melanoma study results - Investing.com Australia
Perspective Therapeutics (NYSE:CATX) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Market Recap: Perspective Therapeutics Inc (CATX)’s Negative Momentum, Closing at 12.66 - The Dwinnex
Analyzing Perspective Therapeutics Inc (CATX) After Recent Trading Activity - Knox Daily
Truist sees overreaction to Perspective Therapeutics stock, calls it 'buying opportunity' - Investing.com Australia
Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies - Yahoo Finance
Oppenheimer highlights competitive edge for Perspective Therapeutics stock amid MC1R data updates - Investing.com South Africa
CATX’s 52-Week Rollercoaster: From $2.20 to $19.05 – What’s Next for Investors? - The InvestChronicle
S&P 500 Moves Higher; BlackRock Reports Upbeat Results - Benzinga
Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Oppenheimer - MarketBeat
Perspective Therapeutics (NYSE:CATX) Shares Gap DownWhat's Next? - MarketBeat
Perspective Therapeutics Shares Fall After Melanoma Study Data Analysis - MarketWatch
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report - Benzinga
CATX’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
Stoke Therapeutics Inc (STOK)’s stock chart: A technical perspective - US Post News
Perspective stock plunges after trial data (NYSE:CATX) - Seeking Alpha
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research - The Manila Times
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research - The Manila Times
F.N.B. Corp. [FNB] Shares Rise 1.10 % on Wednesday - Knox Daily
Taking a look at what insiders are doing to gauge the Perspective Therapeutics Inc (CATX)’s direction - Knox Daily
Perspective Therapeutics (NYSE:CATX) Shares Down 3.6%Here's What Happened - MarketBeat
10 Small Cap Stocks with High Potential - Insider Monkey
TransCode Therapeutics Inc (RNAZ)’s stock chart: A technical perspective - US Post News
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day - The Manila Times
Point72 Asset Management L.P. Sells 13,250,683 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - MarketBeat
New Outlook On Perspective Therapeutics Inc - Stocks Register
What is Perspective Therapeutics Inc (CATX) Stock Return on Shareholders’ Capital? - SETE News
Market Recap Check: Perspective Therapeutics Inc (CATX)’s Positive Finish at 13.21, Up/Down 4.59 - The Dwinnex
Wedbush Comments on Perspective Therapeutics, Inc.'s Q3 2024 Earnings (NYSE:CATX) - MarketBeat
1.13%
0.17%
Kapitalisierung:
|
Volumen (24h):